Northern Trust Corp Raises Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Northern Trust Corp grew its position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 11.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 283,599 shares of the company’s stock after purchasing an additional 28,393 shares during the quarter. Northern Trust Corp owned approximately 0.39% of Kiniksa Pharmaceuticals worth $5,610,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in KNSA. KLP Kapitalforvaltning AS purchased a new position in shares of Kiniksa Pharmaceuticals during the fourth quarter worth about $158,000. Tower Research Capital LLC TRC grew its holdings in shares of Kiniksa Pharmaceuticals by 117.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,483 shares of the company’s stock worth $168,000 after purchasing an additional 4,575 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Kiniksa Pharmaceuticals by 12.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company’s stock worth $174,000 after purchasing an additional 1,004 shares during the last quarter. Teacher Retirement System of Texas boosted its stake in shares of Kiniksa Pharmaceuticals by 7.1% during the fourth quarter. Teacher Retirement System of Texas now owns 10,862 shares of the company’s stock worth $215,000 after buying an additional 719 shares during the period. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of Kiniksa Pharmaceuticals during the fourth quarter worth about $258,000. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Insider Buying and Selling at Kiniksa Pharmaceuticals

In other news, CEO Sanj K. Patel sold 2,872 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $27.03, for a total transaction of $77,630.16. Following the completion of the sale, the chief executive officer now directly owns 96,674 shares in the company, valued at approximately $2,613,098.22. This trade represents a 2.89% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Ross Moat sold 18,259 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $20.29, for a total transaction of $370,475.11. Following the sale, the insider now owns 9,415 shares of the company’s stock, valued at approximately $191,030.35. The trade was a 65.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 231,640 shares of company stock valued at $5,669,136. 54.57% of the stock is owned by corporate insiders.

Kiniksa Pharmaceuticals Trading Down 0.1%

Shares of KNSA opened at $26.70 on Wednesday. Kiniksa Pharmaceuticals, Ltd. has a twelve month low of $17.38 and a twelve month high of $28.56. The stock’s 50 day moving average is $23.04 and its two-hundred day moving average is $21.40. The firm has a market capitalization of $1.95 billion, a PE ratio of -190.70 and a beta of 0.07.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its quarterly earnings data on Tuesday, April 29th. The company reported $0.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.09. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The company had revenue of $137.79 million for the quarter, compared to analyst estimates of $128.35 million. During the same quarter in the previous year, the company earned ($0.25) EPS. The firm’s revenue for the quarter was up 72.5% compared to the same quarter last year. On average, sell-side analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.

Analyst Ratings Changes

KNSA has been the subject of several recent research reports. Jefferies Financial Group increased their target price on shares of Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the stock a “buy” rating in a research note on Tuesday, April 29th. Citigroup initiated coverage on shares of Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They set a “buy” rating and a $40.00 target price for the company. Finally, Wedbush reiterated an “outperform” rating and set a $34.00 target price on shares of Kiniksa Pharmaceuticals in a research note on Wednesday, April 16th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $38.80.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.